- Home
- /
- News
- /
- Drug Trials
- /
- November 2017
Drug Trials News for November 2017
Patients with episodic migraine taking erenumab reported significant and meaningful benefits over six months, with reduced migraine days and acute medication use. Fifty percent of patients taking erenumab 140mg had their migraine days cut by at least half – nearly three-fold higher odds compared to placebo. Patients on erenumab reported reduced physical impairment and improved ability to participate in daily activities based on a validated patient-reported outcome tool. Ninety percent of patients completed the six-month study; data reinforce placebo-like safety and tolerability profile of erenumab consistently seen in the entire clinical program.
30 November, 2017
Trial will analyze breath biomarkers to improve understanding of the treatment effects of a novel GSK pipeline drug candidate for COPD
27 November, 2017
Verseon presented preclinical data on its second anticoagulant candidate, VE-2851, at this week’s American Heart Association conference. VE 2851 shows excellent efficacy paired with low bleeding risk in preclinical testing and is expected to enter clinical trials in 2018.
18 November, 2017
Machine learning could improve our ability to determine whether a new drug works in the brain, potentially enabling researchers to detect drug effects that would be missed entirely by conventional statistical tests, finds a new UCL study published on 13th November in Brain.
17 November, 2017
On November 8th, 2017 the first patient in a new clinical study was implanted with a novel drug delivery system, developed by Renishaw, The procedure took place at Karolinska University Hospital in Stockholm, Sweden. The implantation marks the beginning of a joint clinical study between Renishaw and Herantis Pharma. This phase I - II clinical study will investigate the treatment of Parkinson’s disease using Cerebral Dopamine Neurotrophic Factor (CDNF) delivered with Renishaw’s system.
16 November, 2017